GlaxoSmithKline reports its cervical cancer vaccine Cervarix, a likely competitor to Merck's Gardasil, produced immune responses in all women ages 15 to 55 in a clinical study. The company said the study was the first evidence such a vaccine may be effective in women ages 26 and older and also reported the vaccine was "generally safe and well-tolerated."

Full Story:

Related Summaries